Drugs that contain Treprostinil Diolamine
1. Orenitram patents expiration
ORENITRAM's oppositions filed in EPO
ORENITRAM Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6765117 | UNITED THERAP | Process for stereoselective synthesis of prostacyclin derivatives |
Oct, 2017
(6 years ago) | |
| US9050311 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
| US7417070 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2026
(2 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5153222 | UNITED THERAP | Method of treating pulmonary hypertension with benzidine prostaglandins |
Oct, 2014
(9 years ago) | |
| US9278901 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
| US8252839 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
| US9422223 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
| US7544713 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2024
(2 months from now) | |
| US9393203 | UNITED THERAP | Osmotic drug delivery system |
Apr, 2026
(2 years from now) | |
| US8410169 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Feb, 2030
(5 years from now) | |
| US8349892 | UNITED THERAP | Solid formulations of prostacyclin analogs |
Jan, 2031
(6 years from now) | |
| US8747897 | UNITED THERAP | Osmotic drug delivery system |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Indication(I-820) | Oct 18, 2022 |
| New Dosing Schedule(D-156) | Jan 28, 2019 |
| New Dosing Schedule(D-157) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
Market Authorisation Date: 20 December, 2013
Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).; Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically accept...
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of ORENITRAM before it's drug patent expiration?
More Information on Dosage
ORENITRAM family patents
